Biomea Fusion, Inc. (BMEA) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.07
-7% vs avg
5yr avg: 2.22
30Y Low1.0·High2.9
ROE
↓
-152.4%
↑-64% vs avg
5yr avg: -92.9%
30Y Low-207%·High-45%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BMEA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Biomea Fusion, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $70M | $65M | $140M | $495M | $247M | $178M | — | — |
| Enterprise Value | $15M | $11M | $91M | $329M | $137M | $35M | — | — |
| P/E Ratio → | -0.99 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.07 | 2.19 | 2.72 | 2.93 | 2.27 | 0.99 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BMEA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
BMEA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -152.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -152.4% | -152.4% | -125.4% | -84.4% | -57.0% | -45.2% | -206.8% | — |
| ROA | -89.2% | -89.2% | -98.9% | -71.2% | -52.0% | -33.5% | -17.0% | -452.1% |
| ROIC | — | — | -4566.9% | -11884.6% | -360.3% | — | — | — |
| ROCE | -153.8% | -153.8% | -122.4% | -87.8% | -57.4% | -34.4% | -17.5% | — |
BMEA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $56M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.17 | 0.06 | 0.02 | 0.02 | 0.05 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.83 | -0.96 | -0.98 | -1.01 | -0.80 | -11.89 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($56M) exceeds total debt ($2M)
BMEA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Biomea Fusion, Inc.'s current ratio of 5.23x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.84x to 5.23x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.23 | 5.23 | 3.15 | 7.84 | 6.17 | 38.08 | 38.43 | 0.93 |
| Quick Ratio | 5.23 | 5.23 | 3.15 | 7.84 | 6.17 | 38.08 | 38.43 | 0.93 |
| Cash Ratio | 5.03 | 5.03 | 2.69 | 7.74 | 5.92 | 37.42 | 38.11 | 0.84 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
BMEA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Biomea Fusion, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $52M | $36M | $34M | $29M | $24M | $11M | $11M |
Peer Comparison
Compare BMEA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BMEAYou | $70M | -1.0 | — | — | — | — | -152.4% | — | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARVN | $489M | -5.9 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 VYNE | $28M | -1.0 | — | — | 96.0% | -5219.1% | -66.3% | -124.0% | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 ALLO | $463M | -2.2 | — | — | — | — | -53.4% | -41.2% | — |
 BEAM | $3B | -35.8 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -7.7 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $1B | -3.2 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 EDIT | $245M | -1.4 | — | — | 100.0% | -245.2% | -198.1% | — | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in BMEA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in BMEA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs BMEA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationBMEA vs KYMR — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Kymera Therapeutics, Inc..
Compare NowBMEA — Frequently Asked Questions
Quick answers to the most common questions about buying BMEA stock.
What is Biomea Fusion, Inc.'s P/E ratio?
Biomea Fusion, Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
What is Biomea Fusion, Inc.'s ROE?
Biomea Fusion, Inc.'s return on equity (ROE) is -152.4%. The historical average is -111.9%.
Is BMEA stock overvalued?
Based on historical data, Biomea Fusion, Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.